trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['trastuzumab', 'breast', 'destiny-breast04']
destiny-breast04: in a phase 3 trial, trastuzumab deruxtecan resulted in longer progression-free and overall survival than the physician s choice of chemo among patients with her2-low breast cancer. #asco22 
The New England Journal of Medicine (https://t.co/YGfDrRsIhE) is the world’s leading medical journal and website.